Ayşe İpek Akyüz ÜNSAL, Fadime KAHYAOĞLU, Yavuz ÖZORAN, Alpaslan GÖKÇİMEN, Buket DEMİRCİ

Investigating the Effect of Rosuvastatin, Paracetamol and Coadministration of Rosuvastatin and Paracetamol on Ocular Tissue

Objective: Statins and Paracetamol are two drugs that have a high prescription rate all over the world. Possible side effects can easily be augmented because they use the same cytochrome oxidase enzymes in liver. This study aimed to investigate the effect single or combined administration of these drugs on ocular tissues. Materials and Methods: Twenty-eight 12- to 15-month-old rats were divided in four groups: Control, Rosuvastatin (10 mg/kg/day for 7 times a week), Paracetamol (50 mg/kg/day for 5 times a week) and Rosuvastatin (10 mg/kg/day for 7 times a week) + Paracetamol (50 mg/kg/day for 5 times a week) for 8 weeks. At the end of study, intraocular pressure (IOP) was measured and ocular tissues were obtained for histopathological evaluation under anaesthesia with Ketamine and Xylasine (50 mg/kg and 5 mg/kg, respectively). Results: Rosuvastatin showed an IOP dropping effect and paracetamol did not prevent it. Histopathological evaluation mainly revealed retinal nerve fibre layer degeneration. Additionally, different pathological alterations such as corneal oedema and polypoid proliferation were observed in all the treated groups, although they were rare. Conclusion: The IOP dropping effect of rosuvastatin shows that it is safe in glaucoma patients, but this beneficial effect was not observed with Paracetamol. Retinal nerve fibre layer degeneration with both drugs might be one of the reasons for visual disturbances in real life conditions.

Statin, Parasetamol ve Statin-parasetamol Beraber Kullanımının Göz Dokularına Etkisinin Araştırılması

Amaç: Statinler ve Parasetamol, tüm dünyada en çok reçete edilme oranına sahip ilaçlardan ikisidir. Olası yan etkileri, karaciğerde aynı sitokrom enzimini kullanmasına bağlı olarak kolaylıkla artabilir. Bu çalışmayla her bir ilacın ayrı ayrı ya da birlikte kullanımı sonucunda göz dokusuna olan etkisi incelendi. Gereç ve Yöntemler: On iki - on beş aylık 28 sıçan 4 gruba ayrıldı: Kontrol, Rosuvastatin (10 mg/kg/gün, haftada 7 kez), Parasetamol (50 mg/kg/gün, haftada 5 kez) ve Rosuvastatin (10 mg/kg/gün, haftada 7 kez) + Parasetamol (50 mg/kg/gün, haftada 5 kez) 8 hafta boyunca uygulandı. Çalışmanın sonunda, Ketamine ve Ksilasin (50 mg/kg and 5 mg/kg) anestezisi altında, göz içi basıncı (GİB) ölçülüp, göz dokuları histopatolojik inceleme için alındı. Bulgular: Statin GİB düşürücü etkiye sahiptir ve bu etki Parasetamol ile engellenmemektedir. Histopatolojik inceleme başlıca retinal sinir lifi tabakası hasarını ortaya çıkardı. Buna ek olarak, korneal ödem ve polipoid proliferasyon gibi farklı patolojik değişimler tüm tedavi gruplarında görüldü, ancak nadirdi. Sonuç: Statin GİB düşürücü etkisi bu ilacın glokom hastaları için güvenli olduğunu gösterir, ancak bu faydalı etki Parasetamol'de belirlenmedi. Her iki ilaç ile belirlenen retinal sinirde hasar daha çok araştırma gerektirir; vizüel şikayetlerin bir nedeni olabilir.

PDF

___

1. Schmeer C, Kretz A, Isenmann S. Therapeutic potential of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the treatment of retinal and eye diseases. CNS Neurol Disord Drug Targets 2007; 6: 282-7.

2. Borkar DS, Tham VM, Shen E, Parker JV, Uchida A, Vinoya AC, et al. Association Between Statin Use and Uveitis: Results From the Pacific Ocular Inflammation Study. Am J Ophthalmol 2015; 159: 707-13.

3. Mizranita V, Pratisto EH. Statin-associated ocular disorders: the FDA and ADRAC data. Int J Clin Pharm 2015; 37: 844-50.

4. Karbownik A, Bienert A, Płotek W, Grabowski T, CerbinKoczorowska M, Wolc A, et al. Influence of the Time of Intravenous Administrationof Paracetamol on its Pharmacokinetics and Ocular Dispositionin Rabbits. Eur J Drug Metab Pharmacokinet 2017; 42: 489-98.

5. Qian W, Shichi H. Naphthoquinone-Induced cataract in mice: possible involvement of Ca2+ release and calpain activation. J Ocul Pharmacol Ther 2001; 17: 383-92.

6. Pittler SJ, Fliesler SJ, Rapp LM. Novel morphological changes in rat retina induced by intravitreal injection of lovastatin. Exp Eye Res 1992; 54: 149-52.

7. Mohamed N, Meyer D. Intraocular pressure-lowering effect of oralparacetamol and its in vitro corneal penetration properties. Clin Ophthalmol 2013; 7: 219-27.

8. Jampel HD. Effect of oral paracetamol on intraocular pressure: a pilot study. Clin Exp Ophthalmol 2017; 45: 645-7.

9. Schmidt J, Schmitt C, Hockwin O, Paulus U, von Bergmann K. Ocular Drug Safety and HMG-CoA-Reductase Inhibitors. Ophthalmic Res 1994; 26: 352-60.

10. Nassini R, Materazzi S, Andre E, Sartiani L, Aldini G, Trevisani M, et al. Acetaminophen,via its reactive metabolite N-acetyl-pbenzoquinoneimine and transient receptor potential ankyrin-1 stimulation causes neurogenic inflammation in the airwaysand other tissues in rodents. FASEB J 2010; 24: 4904-16.

11. Reshma CS, Sruthi S, Syama S, Gayathri V, Mohanan PV. Assessing the Systemic Toxicity in Rabbits after Sub Acute Exposure to Ocular Irritant Chemicals. Toxicol Res 2015; 31: 49-59.

12. Fraunfelder FW. Ocular hemorrhage possibly the result of HMGCoA reductase inhibitors. J Ocul Pharmacol Ther 2004; 20: 179- 82.